Sophiris Bio Inc SPHS

Healthcare Biotechnology

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.

EXPM:SPHS - Post by User

Sophiris Bio Inc

Bullboard Posts

Post by sandufon Feb 27, 2015 10:01pm

123 Views

Post# 23474864

Dramatic Shift!!

Something is afoot that the average investor is not aware. The trade of in excess of Seven Million shares today with a price as high for the largest trade of well over a $1.00 means that something is happening. I am certainly happy (I think) that I invested another $5,500 Can. to drop my breakeven point from over $13.60 Can to $3.60 Can. recently. Anybody have any ideas or other info.?

Bullboard Posts

Consumer advocacy law firm investigates Microsoft over X-Box data concerns